Predictors of the development of encephalopathy in the patients presenting with diabetes mellitus

Самойлова, Ю. Г.; Новоселова, М. В.; Костюнина, А К; Пирмагомедова, Э Д; Latypov, A V

doi:10.14341/probl201359567-71

Cited by 3 publications

(1 citation statement)

References 25 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Помимо этого, когнитивные нарушения начинаются у больных СД существенно ранее, чем принято считать, -почти в дебюте заболевания [14,15]. В связи с чем важно уделять большее внимание возможностям додементной диагностики когнитивных нарушений при СД и полной своевременной помощи [16,17]. Кроме того, известно, что половина лиц с хроническими заболеваниями, такими как бронхиальная астма, артериальная гипертензия и СД не должным образом придерживаются предписанного режима и пропускают до 21-34% запланированных рекомендаций их лечащих врачей, важной является тренировка памяти как одной из ког-нитивных функций для улучшения течения заболевания, например компенсации СД [18].…”

Section: '2016unclassified

Perspectives for cognitive rehabilitation of patients with diabetes mellitus

et al. 2016

View full text Add to dashboard Cite

Currently, the problem of cognitive dysfunction is becoming increasingly important due to the raising demand for effective intellectual activity in modern society. One of the most significant causes of cognitive dysfunction is dismetabolic nature of the disorder, such as diabetes mellitus, which has recently been gaining prevalence. Much of the resistance of clinical symptoms of diabetic encephalopathy to conventional therapy requires a search for new approaches for solving this problem. Cognitive rehabilitation as a correctional technique has proved a positive effect in terms of the treatment of neurodegenerative diseases of different nature.This review present the ways for correction of cognitive impairment using the method of cognitive rehabilitation in patients with diabetes, its methodology, mechanisms of action and perspectives.

show abstract

Section: '2016unclassified

Perspectives for cognitive rehabilitation of patients with diabetes mellitus

et al. 2016

View full text Add to dashboard Cite

show abstract

Variability of glycemia and cognitive impairment in patients with diabetes mellitus type 1.

et al. 2018

View full text Add to dashboard Cite

Diabetes mellitus type 1 is associated with impaired cognitive function. Based on the results of systematic reviews and meta-analyzes, the most likely modifiable risk factor is the degree of metabolic control, in particular the variability of glycemia. Aims: to determine the influence of the variability of glycemia on cognitive functions in patients with type 1 diabetes mellitus. Material and methods. Design-observational, one-stage, cross-sectional research. We examined 30 patients with type 1 diabetes mellitus who were divided into 2 groups: 1 group (main) with cognitive impairment, and 2 (control) with normal cognitive functions. All patients were screened for cognitive functions using the Montreal scale (MoCa test). For the diagnosis of fluctuations in glucose level, continuous monitoring of glycemia was carried out using the iPro-2 device (Medtronic, USA): mean glycemic mean (MEAN), standard deviation (SD), mean amplitude of glycemic fluctuation (MAGE), long-term glycemic index (CONGA) Glycemia lability index (LI), hypoglycemia risk index (LBGI), hyperglycemia risk index (HBGI), mean hourly rate of glycemic change (MAG). Results. The study revealed that in patients with type 1 diabetes mellitus, cognitive impairment was dominated by a violation of constructive praxis, memory and attention. Recorded a significant difference in MEAN, SD, CONGA, Gindex, LBGI, HBGI, MAGE, Mvalue and MAG. Correlation analysis revealed the relationship of cognitive impairments with the level of HbA1c, as well as the variability parameters MEAN, SD, CONGA, Gindex, LBGI, HBGI, MAGE, Mvalue, MAG. Conclusions. The relationship between the variability of glycemia and cognitive impairment was registered in patients with type 1 diabetes mellitus

show abstract

Laboratory Biomarkers for Brain Damage in Diabetes Mellitus

BYKOV,

MURAVYOVA

2023

View full text Add to dashboard Cite

Objective: This review outlines the literature data on the main laboratory biomarkers of brain damage in diabetes mellitus (DM) type I and II. Neurospecific proteins: S-100 protein, neurospecific enolase, glial fibrillar acidic protein, myelin basic protein, and brain-derived neurotrophic factor (BDNF) are considered specific markers of cerebral dysfunction in DM. Emphasis is placed on pro-inflammatory cytokines (IL-1, IL-6, tumor necrosis factor-α, C-reactive protein), as blood biomarkers, the increase of which indicates brain damage in DM type I and II. High concentrations of adipokines, inflammatory mediators of adipose tissue, are a reliable laboratory sign of brain damage in this endocrinopathy. Advanced glycation end products (AGEs), as pathogenic metabolites of oxidative stress (OS), detected in blood in high concentration, can act as indicators of cognitive deficit in DM. Increased concentration of autoantibodies to some neuroreceptors (dopamine, glutamate) may serve as specific laboratory biomarkers of brain damage in DM type I. Further searches of new laboratory biomarkers of brain dysfunction are needed in order to improve the diagnosis of cerebral insufficiency in DM Keywords: Diabetes mellitus, biomarkers, brain damage, neurospecific proteins, adipokines.

show abstract

Predictors of the development of encephalopathy in the patients presenting with diabetes mellitus

Cited by 3 publications

References 25 publications

Perspectives for cognitive rehabilitation of patients with diabetes mellitus

Perspectives for cognitive rehabilitation of patients with diabetes mellitus

Variability of glycemia and cognitive impairment in patients with diabetes mellitus type 1.

Laboratory Biomarkers for Brain Damage in Diabetes Mellitus

Contact Info

Product

Resources

About